Best's Commentary: Latest Middle East Turmoil Generates Additional, Familiar Exposures for Insurers; Regional Economy May Feel the Broader Brunt
The Best's Commentary, titled 'Latest Middle East Turmoil Generates Additional, Familiar Exposures for Insurers; Regional Economy May Feel the Broader Brunt,' notes that thus far, there has been no ratings impact for AM Best-rated insurers operating in the region. If tensions escalate, there is a potential impact for insurers who underwrite political risk, trade credit and war risk coverages in the Middle East region.
'Disputes over exclusions may arise from ambiguous policy language, particularly in relation to business interruption claims, where coverage and causality may be contested,' said Mahesh Mistry, senior director, AM Best. 'For example, port closures, logistical delays, and production halts could potentially trigger business interruption claims.'
AM Best also notes in the report that a significant impact is evident in the aviation and marine insurance specialty markets. Premiums for ships operating in the Persian Gulf region, particularly through the Strait of Hormuz, have risen sharply to reflect the elevated risk. Aviation insurers have similarly raised rates for carriers flying near the conflict zones.
Many countries in the Gulf Cooperation Council (GCC) region are heavily reliant upon the hydrocarbon sector to drive economic growth, according to the report. The GCC comprises Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. AM Best maintained its stable outlook on the GCC in April, but notes that this region could be adversely impacted by second-order effects. 'If events were to escalate and impact energy prices, it is likely to affect opportunities for insurers in the region,' said Ann Modica, director, AM Best. 'Any wider escalation into the GCC region could affect energy prices, and may have repercussions for inflation globally.'
To access the full copy of the Best's Commentary on the Middle East, please visit http://www3.ambest.com/bestweek/purchase.asp?record_code=355185.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
17 minutes ago
- Associated Press
Growth of Drive-thru and Delivery Services Increases Demand for Advanced Holding Units and Packaging Solutions
DUBLIN--(BUSINESS WIRE)--Jul 3, 2025-- The 'Quick Service Restaurant (QSR) Equipment Market Size, Share, Trends, Analysis, and Forecast 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and Challenges' report has been added to offering. The Global Quick Service Restaurant (QSR) Equipment Market Size is valued at USD 24.48 Billion in 2025. Worldwide sales of Quick Service Restaurant (QSR) Equipment Market are expected to grow at a significant CAGR of 6.5%, reaching USD 38.15 Billion by the end of the forecast period in 2034. The quick service restaurant (QSR) equipment market has become a cornerstone of the foodservice industry, driven by the global expansion of fast-food chains, convenience-focused dining trends, and rising consumer expectations for quality and efficiency. QSR equipment encompasses a broad range of tools and appliances, including cooking and holding units, beverage dispensers, refrigeration systems, and point-of-sale technology. With the growing demand for speed and consistency in meal preparation, QSR operators rely on high-performance equipment to maintain operational efficiency, ensure food safety, and meet customers' expectations for quick, fresh, and customizable meals. Technological advancements, such as energy-efficient cooking appliances, touchscreen interfaces, and smart kitchen solutions, have significantly enhanced the capabilities of QSR equipment, enabling restaurants to streamline operations, reduce waste, and improve overall productivity. As the QSR industry continues to grow, so does the demand for innovative equipment designed to meet evolving consumer preferences and regulatory standards. Many QSRs are adopting more sustainable practices, including the use of energy-efficient appliances and waste-reduction technologies. The shift toward healthier menu options has also spurred the need for specialized equipment capable of preparing fresh, minimally processed ingredients while maintaining fast service speeds. In addition, the rise of delivery and drive-thru services has created demand for more advanced holding units, automated ordering systems, and efficient packaging solutions. Although the market faces challenges such as high upfront costs, maintenance concerns, and supply chain disruptions, ongoing R&D efforts, strong brand partnerships, and a focus on sustainability are shaping a resilient, innovation-driven QSR equipment market. Key Takeaways Key Attributes: Companies Featured Quick Service Restaurant (QSR) Equipment Market Segmentation By Type By Application By End User By Technology By Distribution Channel For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: RETAIL RESTAURANT/BAR OTHER MANUFACTURING MANUFACTURING SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 07/03/2025 12:35 PM/DISC: 07/03/2025 12:35 PM
Associated Press
27 minutes ago
- Associated Press
Rising Popularity of Remote Work Elevates Demand for Caravans with Modern Amenities
DUBLIN--(BUSINESS WIRE)--Jul 3, 2025-- The 'Caravans Market Outlook 2025-2034" report has been added to offering. Caravans Market is valued at USD 14.9 billion in 2025. Further the market is expected to grow by a CAGR of 5.6% to reach global sales of USD 24.4 billion in 2034 The caravans market has experienced steady growth as consumers increasingly seek flexible and comfortable travel options. Caravans, also known as travel trailers or camper vans, offer a home-on-wheels experience, allowing travelers to explore various destinations without compromising on comfort or convenience. This market encompasses a wide range of products, from compact teardrop trailers to luxurious motorhomes, catering to different budgets, preferences, and travel needs. One of the key trends shaping the caravans market is the rising demand for eco-friendly and energy-efficient models. Many manufacturers are integrating solar panels, energy-efficient appliances, and sustainable materials into their designs. Additionally, the popularity of remote work and digital nomad lifestyles has driven the demand for caravans equipped with workspaces, reliable internet connectivity, and modern amenities. This trend has encouraged innovation in layout design, storage solutions, and off-grid capabilities. Regionally, North America and Europe have been the largest markets for caravans, supported by a well-established camping culture, extensive road networks, and strong leisure travel industries. Meanwhile, the Asia-Pacific region is emerging as a key growth area, driven by rising disposable incomes, an expanding middle class, and growing interest in outdoor recreation. As consumer preferences evolve and manufacturers continue to innovate, the caravans market is poised for sustained growth and diversification. Key Insights Caravans Market Your Takeaways From this Report Key Attributes: Companies Featured Caravans Market Segmentation By Type By Price By Application By Geography For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: OTHER AUTOMOTIVE RECREATIONAL VEHICLES PERFORMANCE & SPECIAL INTEREST AUTOMOTIVE SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 07/03/2025 12:28 PM/DISC: 07/03/2025 12:28 PM
Associated Press
27 minutes ago
- Associated Press
Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook to 2031: United States and China Lead Global Gamma Delta T Cell Therapy Clinical Trials
DUBLIN--(BUSINESS WIRE)--Jul 3, 2025-- The 'Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031" report has been added to offering. Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031 Report Conclusions: Adoptive gamma delta T cell therapy is a novel type of immunotherapy that utilizes a unique subset of T cells to recognize and destroy cancer cells. While typical alpha-beta (aß) T cells identify antigens presented by major histocompatibility complex (MHC) molecules, gamma delta T cells are activated by stress induced ligands and phosphoantigens in an MHC independent fashion. This enables them to detect and target a wide variety of tumor types, including those that are not targeted by conventional immune vigilance. gamma delta T cells possess characteristics of both innate and adaptive immunity, allowing them to have the ability for immediate response and immune memory, which make them particularly good candidates for off-the-shelf adoptive cell therapies. In cancer, gamma delta T cells are under investigation for their potential to destroy malignant cells without the requirement of tumor-specific antigens or genetic modifications, which are technically demanding and expensive. Their intrinsic cytotoxicity, along with the possibility of allogeneic utilization (from healthy donors), provides access to the availability of mass producible, inexpensive therapies. The majority of clinical research and development to date has been in hematological malignancies, where they have been especially promising. Gamma delta T cells are able to penetrate the bone marrow and other lymphoid organs and exert tumor effects there through cytokine release, direct cytotoxicity, and changing the microenvironment of the tumor. The demand for novel cancer therapies is pressing, especially in blood cancers like acute myeloid leukemia (AML), which tend to relapse or are resistant to conventional therapies. Options for patients who relapse following remission or who have residual disease (MRD) are limited, and prognosis is usually poor. Gamma delta T cell therapies are in a unique position to bridge this gap, providing a potentially effective, safe, and off-the-shelf product that can be delivered without the logistical issues of autologous T cell therapies, including manufacturing hold-ups or patient variability. TC Biopharm is leading the way in clinical development in this area. The company's most advanced product candidate, OmnImmune (formerly TCB-002), is in a pivotal Phase 2/3 trial for AML. OmnImmune is an allogeneic gamma delta T cell therapy engineered to quickly target and destroy cancer cells while avoiding damage to normal tissue. This clinical program is one of the most advanced in the global gamma delta T cell pipeline, highlighting TC Biopharm's growing leadership within the domain. Besides OmnImmune, the company has a number of other gamma delta T cell candidates in development for various cancer indications. One of the most significant recent advances from TC Biopharm is the development of its candidate TCB008, which is under investigation in the Phase 2 ACHIEVE trial. The firm reported in June 2025 that the first patient in Cohort B, who had relapsed previously with detectable MRD, reached complete molecular remission following two doses. A lack of detectable NPM1 transcripts after treatment signifies a profound and lasting response, which identifies TCB008 as a promising post-remission therapy for blood cancers. This achievement demarcates the potent, targeted immune function of gamma delta T cells and substantiates their role as a new therapeutic strategy. Globally, most of the research studies on gamma delta T cells remains on hematologic malignancies, and there are fewer programs directed at solid tumors. This is partly a result of the more sophisticated microenvironments and the immune evasion mechanisms utilized by solid cancers. However, attempts are being made to apply gamma delta T cell treatments to these more difficult contexts. Geographically, US-based players dominate the gamma delta T cell therapy market, followed by increasing numbers of Chinese firms. These regions have made heavy investment in cell therapy facilities and technology, facilitating quicker translation from bench to bedside. Moving forward, the prospects for gamma delta T cell therapy are bright but will necessitate continued clinical validation, most importantly in solid tumors. With advances in manufacturing technologies and biomarker-driven strategies, the use of gamma delta T cells may extend to more types of cancers. With leaders such as TC Biopharm at the forefront, the field is on track to provide life changing treatments for critical unmet needs in cancer domain. Company Coverage: Key Topics Covered: 1. Introduction To Gamma Delta T Cell Therapy 1.1 Emerging Role of T Cell Based Immunotherapies 1.2 Overview of Gamma Delta T Cell Therapy 1.3 Gamma Delta T Cell Therapy v/s Conventional Therapies 2. Role of Gamma Delta T Cells in Cancer 2.1 Gamma Delta T Cells in Cancer Progression 2.2 Anti Tumor Activity of Gamma Delta T Cells 2.3 Adopted Approaches for Gamma Delta T Cell Therapy 3. Advanced Combination Strategies In Gamma Delta T Cell Therapy 4. Gamma Delta T Cell Therapy Market Overview 4.1 Current Market Scenario 4.2 Future R&D & Commercial Opportunities 4.3 Market Potential of Gamma Delta T Cell Therapy Market 4.4 Technology Platforms For Gamma Delta T Cell Therapy 4.5 Favorable Market Growth Parameters 4.6 Key Challenges To Overcome For Future Growth 5. Global Gamma Delta T Cell Therapy Clinical Trials Overview 5.1 By Phase 5.2 By Country 5.3 By Company 5.4 By Indication 5.5 By Priority Status 6. Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication & Phase 6.1 Research 6.2 Preclinical 6.3 Phase I 6.4 Phase I/II 6.5 Phase II 6.6 Phase II/III 7. Gamma Delta T Cell Therapy In Leukemia 7.1 Ongoing Clinical Research & Development Trends 7.2 Future Market Opportunity of Gamma Delta T Cells In Leukemia 8. Gamma Delta T Cell Therapy In Lung Cancer 8.1 Ongoing Clinical Research & Development Trends 8.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Lung Cancer 9. Gamma Delta T Cells In Breast Cancer 9.1 Ongoing Clinical Research & Development Trends 9.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Breast Cancer 10. Gamma Delta T Cells in Colorectal Cancer 10.1 Ongoing Clinical Research & Development Trends 10.2 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer 11. Gamma Delta T Cells In Pancreatic Cancer 11.1 Ongoing Clinical Research & Development Trends 11.2 Future Market Potential of Gamma Delta Therapy In Pancreatic Cancer 12. Gamma Delta T Cells In Lymphoma 12.1 Ongoing Clinical Research & Development Trends 12.2 Future Market Potential of Gamma Delta Therapy In Lymphoma 13. Gamma Delta T Cell Therapy In Brain Tumors 13.1 Research & Development In Brain Tumors 13.2 Future Market Potential of Gamma Delta Therapy In Brain Tumors 14. Gamma Delta T Cell Therapy In Head & Neck Cancer 14.1 Research & Development In Head & Neck Cancer 14.2 Future Market Potential of Gamma Delta Therapy In Head & Neck Cancer 15. Competitive Landscape 15.1 Acepodia 15.2 Adicet 15.3 Appia Bio 15.4 Cytomed Therapeutics 15.5 Century Therapeutics 15.6 Expression Therapeutics 15.7 Immatics 15.8 IN8bio 15.9 JY BioMed 15.10 Legend Biotech 15.11 Luminary Therapeutics 15.12 PhosphoGam 15.13 Takeda 15.14 TC Biopharm 15.15 ViGenCell For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH GENETICS PHARMACEUTICAL ONCOLOGY SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 07/03/2025 12:19 PM/DISC: 07/03/2025 12:19 PM
